CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Financials Charles River Laboratories International, Inc. Börse Stuttgart
Equities
RV6
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 199.4 EUR | -2.04% |
|
+4.34% | -6.19% |
| 06-07 | The job report just threw a spanner in the works |  |
| 06-07 | Mizuho Initiates Charles River Laboratories International With Neutral Rating, $235 Price Target | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,416 | 12,366 | 18,969 | 11,086 | 12,127 | 11,064 | - | - |
| Enterprise Value (EV) 1 | 9,066 | 14,117 | 21,394 | 13,564 | 14,497 | 13,023 | 12,512 | 11,941 |
| P/E ratio | 29.9 x | 34.5 x | 49.5 x | 23 x | 25.6 x | 27.2 x | 22 x | 18.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.83 x | 4.23 x | 5.36 x | 2.79 x | 2.94 x | 2.62 x | 2.44 x | 2.27 x |
| EV / Revenue | 3.46 x | 4.83 x | 6.04 x | 3.41 x | 3.51 x | 3.09 x | 2.76 x | 2.45 x |
| EV / EBITDA | 15 x | 20.1 x | 24.3 x | 13.7 x | 14.3 x | 12.3 x | 10.7 x | 9.29 x |
| EV / FCF | 26.6 x | 37.1 x | 40.2 x | 46 x | 39.7 x | 29.5 x | 23 x | 19.6 x |
| FCF Yield | 3.75% | 2.69% | 2.49% | 2.17% | 2.52% | 3.39% | 4.34% | 5.1% |
| Price to Book | 4.55 x | 5.85 x | 7.46 x | 3.73 x | 3.37 x | 2.73 x | 2.38 x | 2.08 x |
| Nbr of stocks (in thousands) | 48,839 | 49,743 | 50,464 | 50,879 | 51,297 | 51,512 | - | - |
| Reference price 2 | 151.8 | 248.6 | 375.9 | 217.9 | 236.4 | 214.8 | 214.8 | 214.8 |
| Announcement Date | 11/02/20 | 17/02/21 | 16/02/22 | 22/02/23 | 14/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,621 | 2,924 | 3,540 | 3,976 | 4,129 | 4,221 | 4,530 | 4,870 |
| EBITDA 1 | 604.4 | 701.3 | 879.5 | 990.9 | 1,013 | 1,063 | 1,172 | 1,285 |
| EBIT 1 | 497.2 | 585 | 742.1 | 834 | 838.8 | 868.6 | 978.2 | 1,072 |
| Operating Margin | 18.97% | 20.01% | 20.96% | 20.97% | 20.31% | 20.58% | 21.59% | 22.02% |
| Earnings before Tax (EBT) 1 | 304.1 | 447.1 | 480.7 | 623 | 581.3 | 533.8 | 688.9 | 821.5 |
| Net income 1 | 252 | 364.3 | 391 | 486.2 | 474.6 | 404.6 | 519.3 | 617.5 |
| Net margin | 9.61% | 12.46% | 11.04% | 12.23% | 11.49% | 9.58% | 11.46% | 12.68% |
| EPS 2 | 5.070 | 7.200 | 7.600 | 9.480 | 9.220 | 7.910 | 9.770 | 11.76 |
| Free Cash Flow 1 | 340.4 | 380 | 532 | 294.9 | 365.4 | 442.1 | 543.5 | 609.1 |
| FCF margin | 12.99% | 13% | 15.03% | 7.42% | 8.85% | 10.47% | 12% | 12.51% |
| FCF Conversion (EBITDA) | 56.32% | 54.19% | 60.5% | 29.76% | 36.06% | 41.61% | 46.37% | 47.4% |
| FCF Conversion (Net income) | 135.08% | 104.31% | 136.07% | 60.65% | 76.98% | 109.28% | 104.65% | 98.63% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 11/02/20 | 17/02/21 | 16/02/22 | 22/02/23 | 14/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 905 | 913.9 | 973.1 | 989.2 | 1,100 | 1,029 | 1,060 | 1,027 | 1,013 | 1,012 | 1,024 | 1,069 | 1,114 | 1,089 | 1,103 |
| EBITDA 1 | 226.9 | 233.2 | 250.4 | 240.4 | 266.9 | 259.8 | 259.5 | 255.4 | 238.5 | 233.1 | 242.7 | 284.9 | 304.4 | 262.5 | 269.1 |
| EBIT 1 | 189.1 | 196 | 211.7 | 201.4 | 224.8 | 217.8 | 216.2 | 210.9 | 193.9 | 187.4 | 195.9 | 237.3 | 254.7 | 224.4 | 232.5 |
| Operating Margin | 20.89% | 21.45% | 21.75% | 20.36% | 20.44% | 21.16% | 20.4% | 20.54% | 19.14% | 18.53% | 19.14% | 22.19% | 22.87% | 20.61% | 21.07% |
| Earnings before Tax (EBT) 1 | 163.6 | 110.8 | 144.1 | 123.1 | 244.9 | 131 | 128.7 | 112.9 | 208.7 | 99.01 | 110.2 | 156 | 168.6 | 149.8 | 156.9 |
| Net income 1 | 137.6 | 93.02 | 109.3 | 96.47 | 187.4 | 103.1 | 97.02 | 87.39 | 187.1 | 67.33 | 82.89 | 118.1 | 127.8 | 113.3 | 118.8 |
| Net margin | 15.2% | 10.18% | 11.23% | 9.75% | 17.04% | 10.02% | 9.15% | 8.51% | 18.46% | 6.66% | 8.1% | 11.04% | 11.48% | 10.41% | 10.77% |
| EPS 2 | 2.670 | 1.810 | 2.130 | 1.880 | 3.650 | 2.010 | 1.890 | 1.690 | 3.620 | 1.300 | 1.727 | 2.253 | 2.563 | 2.080 | 2.260 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 16/02/22 | 04/05/22 | 03/08/22 | 02/11/22 | 22/02/23 | 11/05/23 | 09/08/23 | 08/11/23 | 14/02/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 1,650 | 1,751 | 2,425 | 2,477 | 2,370 | 1,959 | 1,447 | 877 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.73 x | 2.497 x | 2.758 x | 2.5 x | 2.339 x | 1.844 x | 1.235 x | 0.6823 x |
| Free Cash Flow 1 | 340 | 380 | 532 | 295 | 365 | 442 | 543 | 609 |
| ROE (net income / shareholders' equity) | 22.7% | 22% | 22.8% | 20.7% | 16.7% | 14.8% | 14.5% | 13.9% |
| ROA (Net income/ Total Assets) | 7.82% | 8.08% | 8.48% | 7.8% | 6.95% | 6.74% | 6.7% | 6.75% |
| Assets 1 | 3,222 | 4,508 | 4,612 | 6,232 | 6,830 | 6,001 | 7,748 | 9,150 |
| Book Value Per Share 2 | 33.40 | 42.50 | 50.40 | 58.40 | 70.10 | 78.80 | 90.20 | 103.0 |
| Cash Flow per Share 2 | 9.680 | 10.80 | 15.10 | 12.10 | 13.30 | 15.80 | 16.50 | 18.30 |
| Capex 1 | 141 | 167 | 229 | 325 | 319 | 305 | 325 | 345 |
| Capex / Sales | 5.36% | 5.7% | 6.46% | 8.17% | 7.71% | 7.23% | 7.18% | 7.07% |
| Announcement Date | 11/02/20 | 17/02/21 | 16/02/22 | 22/02/23 | 14/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
214.8
USD
Average target price
267.3
USD
Spread / Average Target
+24.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +51.85% | 57.87B | |
| +41.42% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- CRL Stock
- RV6 Stock
- Financials Charles River Laboratories International, Inc.